Post-Traumatic Stress Disorder (PTSD)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Post-Traumatic Stress Disorder

MalaCards integrated aliases for Post-Traumatic Stress Disorder:

Name: Post-Traumatic Stress Disorder 12 29 42 15 17 70 32
Ptsd 12 48
Stress Disorders, Post-Traumatic 44
Post Traumatic Stress Disorder 73
Posttraumatic Stress Disorder 15
Traumatic Neurosis 12


External Ids:

Disease Ontology 12 DOID:2055
ICD9CM 34 309.81
MeSH 44 D013313
NCIt 50 C3389
SNOMED-CT 67 192415000
ICD10 32 F43.1
UMLS 70 C0038436

Summaries for Post-Traumatic Stress Disorder

MedlinePlus : 42 What is post-traumatic stress disorder (PTSD)? Post-traumatic stress disorder (PTSD) is a mental health disorder that some people develop after they experience or see a traumatic event. The traumatic event may be life-threatening, such as combat, a natural disaster, a car accident, or sexual assault. But sometimes the event is not necessarily a dangerous one. For example, the sudden, unexpected death of a loved one can also cause PTSD. It's normal to feel afraid during and after a traumatic situation. The fear triggers a "fight-or-flight" response. This is your body's way of helping to protect itself from possible harm. It causes changes in your body such as the release of certain hormones and increases in alertness, blood pressure, heart rate, and breathing. In time, most people recover from this naturally. But people with PTSD don't feel better. They feel stressed and frightened long after the trauma is over. In some cases, the PTSD symptoms may start later on. They might also come and go over time. What causes post-traumatic stress disorder (PTSD)? Researchers don't know why some people get PTSD and others don't. Genetics, neurobiology, risk factors, and personal factors may affect whether you get PTSD after a traumatic event. Who is at risk for post-traumatic stress disorder (PTSD)? You can develop PTSD at any age. Many risk factors play a part in whether you will develop PTSD. They include Your sex; women are more likely to develop PTSD Having had trauma in childhood Feeling horror, helplessness, or extreme fear Going through a traumatic event that lasts a long time Having little or no social support after the event Dealing with extra stress after the event, such as loss of a loved one, pain and injury, or loss of a job or home Having a history of mental illness or substance use What are the symptoms of post-traumatic stress disorder (PTSD)? There are four types of PTSD symptoms, but they may not be the same for everyone. Each person experiences symptoms in their own way. The types are Re-experiencing symptoms, where something reminds you of the trauma and you feel that fear again. Examples include Flashbacks, which cause you to feel like you are going through the event again Nightmares Frightening thoughts Avoidance symptoms, where you try to avoid situations or people that trigger memories of the traumatic event. This may cause you to Stay away from places, events, or objects that are reminders of the traumatic experience. For example, if you were in a car accident, you might stop driving. Avoiding thoughts or feelings related to the traumatic event. For example, you might try to stay very busy to try to avoid thinking about what happened. Arousal and reactivity symptoms, which may cause you to be jittery or be on the lookout for danger. They include Being easily startled Feeling tense or "on edge" Having difficulty sleeping Having angry outbursts Cognition and mood symptoms, which are negative changes in beliefs and feelings. They include Trouble remembering important things about the traumatic event Negative thoughts about yourself or the world Feeling blame and guilt No longer being interested in things you enjoyed Trouble concentrating The symptoms usually start soon after the traumatic event. But sometimes they may not appear until months or years later. They also may come and go over many years. If your symptoms last longer than four weeks, cause you great distress, or interfere with your work or home life, you might have PTSD. How is post-traumatic stress disorder (PTSD) diagnosed? A health care provider who has experience helping people with mental illnesses can diagnose PTSD. The provider will do a mental health screening and may also do a physical exam. To get a diagnosis of PTSD, you must have all of these symptoms for at least one month: At least one re-experiencing symptom At least one avoidance symptom At least two arousal and reactivity symptoms At least two cognition and mood symptoms What are the treatments for post-traumatic stress disorder (PTSD)? The main treatments for PTSD are talk therapy, medicines, or both. PTSD affects people differently, so a treatment that works for one person may not work for another. If you have PTSD, you need to work with a mental health professional to find the best treatment for your symptoms. Talk therapy, or psychotherapy, which can teach you about your symptoms. You will learn how to identify what triggers them and how to manage them. There are different types of talk therapy for PTSD. Medicines can help with the symptoms of PTSD. Antidepressants may help control symptoms such as sadness, worry, anger, and feeling numb inside. Other medicines can help with sleep problems and nightmares. Can post-traumatic stress disorder (PTSD) be prevented? There are certain factors that can help reduce the risk of developing PTSD. These are known as resilience factors, and they include Seeking out support from other people, such as friends, family, or a support group Learning to feel good about your actions in the face of danger Having a coping strategy or a way of getting through the bad event and learning from it Being able to act and respond effectively despite feeling fear Researchers are studying the importance of the resilience and risk factors for PTSD. They are also studying how genetics and neurobiology can affect the risk of PTSD. With more research, someday it may be possible to predict who is likely to develop PTSD. This could also help in finding ways to prevent it. NIH: National Institute of Mental Health

MalaCards based summary : Post-Traumatic Stress Disorder, also known as ptsd, is related to acute stress disorder and traumatic brain injury, and has symptoms including nervousness An important gene associated with Post-Traumatic Stress Disorder is LINC01090 (Long Intergenic Non-Protein Coding RNA 1090), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Dronabinol and Tramadol have been mentioned in the context of this disorder. Affiliated tissues include brain, amygdala and eye, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 An anxiety disorder which results from a traumatic experience that results in psychological trauma.

Wikipedia : 73 Post-traumatic stress disorder (PTSD)[note 1] is a mental disorder that one can develop after exposure... more...

Related Diseases for Post-Traumatic Stress Disorder

Diseases related to Post-Traumatic Stress Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 533)
# Related Disease Score Top Affiliating Genes
1 acute stress disorder 33.0 SLC6A4 NR3C1 FKBP5 CRP CRH BDNF
2 traumatic brain injury 32.7 IL1B DRD2 COMT BDNF
3 brain injury 32.0 IL1B DRD2 COMT BDNF
4 depression 31.8 SLC6A4 NR3C1 MAOA HTR2A CRH BDNF
5 alcohol use disorder 31.6 SLC6A4 HTR2A DRD2 CRH COMT BDNF
6 sexual disorder 31.3 SLC6A4 HTR2A BDNF
7 adjustment disorder 31.3 SLC6A4 HTR2A CRH BDNF
8 somatization disorder 31.3 SLC6A4 CRH COMT
9 panic disorder 31.3 SLC6A4 MAOA HTR2A DRD2 CRH COMT
10 neurotic disorder 31.2 SLC6A4 MAOA HTR2A COMT BDNF
11 sleep apnea 31.2 SLC6A4 IL1B HTR2A CRP BDNF
12 alexithymia 31.2 SLC6A4 OXTR DRD2 CRP COMT
13 sleep disorder 31.2 SLC6A4 IL1B HTR2A CRP CRH COMT
14 dementia 31.1 MAOB HTR2A DRD2 COMT BDNF
15 mental depression 31.0 SLC6A4 OXTR NR3C1 MAOA IL1B HTR2A
16 substance abuse 31.0 SLC6A4 MAOA HTR2A DRD2 DBH CRP
17 substance dependence 31.0 SLC6A4 MAOA DRD2 CRH COMT CNR1
18 mood disorder 31.0 SLC6A4 NR3C1 MAOB MAOA HTR2A DRD2
19 postpartum depression 31.0 SLC6A4 OXTR NR3C1 MAOA CRH COMT
20 psychotic disorder 30.9 SLC6A4 MAOB MAOA HTR2A DRD2 DBH
21 personality disorder 30.9 SLC6A4 OXTR NR3C1 MAOB MAOA HTR2A
22 agoraphobia 30.9 SLC6A4 MAOA HTR2A CRH COMT
23 borderline personality disorder 30.9 SLC6A4 OXTR NR3C1 MAOA HTR2A FKBP5
24 dissociative disorder 30.9 SLC6A4 FKBP5 BDNF
25 generalized anxiety disorder 30.8 SLC6A4 NR3C1 MAOA HTR2A DRD2 CRP
26 opiate dependence 30.8 SLC6A4 DRD2 CRH
27 fibromyalgia 30.8 SLC6A4 PREP IL1B HTR2A CRP CRH
28 social phobia 30.8 SLC6A4 MAOA HTR2A DRD2 CRH COMT
29 drug dependence 30.8 SLC6A4 DRD2 CRH CNR1 BDNF
30 obsessive-compulsive personality disorder 30.8 SLC6A4 HTR2A COMT
31 conduct disorder 30.8 SLC6A4 OXTR MAOA DRD2 DBH COMT
32 pure autonomic failure 30.8 MAOB MAOA DBH
33 cocaine dependence 30.7 SLC6A4 HTR2A DRD2 DBH COMT CNR1
34 bulimia nervosa 30.7 SLC6A4 MAOA HTR2A DRD2 COMT BDNF
35 major depressive disorder 30.7 SLC6A4 OXTR NR3C1 MAOB MAOA IL1B
36 pulmonary disease, chronic obstructive 30.7 SLC6A4 NR3C1 IL1B CRP
37 movement disease 30.7 MAOB DRD2 COMT BDNF
38 eating disorder 30.7 SLC6A4 OXTR HTR2A FAAH DRD2 CRH
39 irritable bowel syndrome 30.6 SLC6A4 IL1B HTR2A CRP CRH COMT
40 pain agnosia 30.6 IL1B FAAH CRH COMT CNR1 BDNF
41 dysthymic disorder 30.6 SLC6A4 MAOA HTR2A CRP CRH COMT
42 separation anxiety disorder 30.6 SLC6A4 OXTR MAOA COMT
43 heroin dependence 30.6 SLC6A4 MAOA HTR2A DRD2 COMT BDNF
44 asthma 30.6 SLC6A4 NR3C1 IL1B FKBP5 CRH COMT
45 bipolar i disorder 30.6 SLC6A4 HTR2A DRD2 COMT BDNF
46 obsessive-compulsive disorder 30.6 SLC6A4 OXTR MAOB MAOA IL1B HTR2A
47 anorexia nervosa 30.6 SLC6A4 MAOA HTR2A CRH COMT CNR1
48 alcohol dependence 30.6 SLC6A4 MAOB MAOA IL1B HTR2A FAAH
49 hypochondriasis 30.6 SLC6A4 HTR2A BDNF
50 withdrawal disorder 30.5 FAAH CRH CNR1

Comorbidity relations with Post-Traumatic Stress Disorder via Phenotypic Disease Network (PDN):

Anxiety Dysthymic Disorder
Major Depressive Disorder

Graphical network of the top 20 diseases related to Post-Traumatic Stress Disorder:

Diseases related to Post-Traumatic Stress Disorder

Symptoms & Phenotypes for Post-Traumatic Stress Disorder

UMLS symptoms related to Post-Traumatic Stress Disorder:


MGI Mouse Phenotypes related to Post-Traumatic Stress Disorder:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 ADCYAP1 ADCYAP1R1 BDNF CNR1 COMT CRH
2 homeostasis/metabolism MP:0005376 10.25 ADCYAP1 ADCYAP1R1 BDNF CNR1 COMT CRH
3 growth/size/body region MP:0005378 10.18 ADCYAP1 ADCYAP1R1 BDNF CNR1 CRH DBH
4 nervous system MP:0003631 10.09 ADCYAP1 ADCYAP1R1 BDNF CNR1 COMT CRH
5 endocrine/exocrine gland MP:0005379 10.06 BDNF COMT CRH DBH DRD2 HTR2A
6 integument MP:0010771 9.96 BDNF CNR1 CRH DBH DRD2 FAAH
7 no phenotypic analysis MP:0003012 9.56 ADCYAP1 ADCYAP1R1 BDNF CNR1 CRH DRD2
8 normal MP:0002873 9.36 ADCYAP1R1 BDNF CNR1 CRH DBH DRD2

Drugs & Therapeutics for Post-Traumatic Stress Disorder

Drugs for Post-Traumatic Stress Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 317)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
Ziprasidone Approved Phase 4 146939-27-7 60854
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Cycloserine Approved Phase 4 68-41-7 401 6234
Memantine Approved, Investigational Phase 4 19982-08-2 4054
Mianserin Approved, Investigational Phase 4 24219-97-4 4184
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
Asenapine Approved Phase 4 85650-56-2, 65576-45-6 3001386
Haloperidol Approved Phase 4 52-86-8 3559
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
Promethazine Approved, Investigational Phase 4 60-87-7 4927
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
Suvorexant Approved, Investigational Phase 4 1030377-33-3
Pimavanserin Approved, Investigational Phase 4 706779-91-1 16058810
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
Sertraline Approved Phase 4 79617-96-2 68617
Propranolol Approved, Investigational Phase 4 525-66-6 4946
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
34 Olive Phase 4
35 Serotonin 5-HT3 Receptor Antagonists Phase 4
36 Serotonin 5-HT1 Receptor Agonists Phase 4
37 Narcotic Antagonists Phase 4
38 Antimetabolites Phase 4
39 glucocorticoids Phase 4
40 Antineoplastic Agents, Hormonal Phase 4
Histamine Phosphate Phase 4 51-74-1 65513
42 Gastrointestinal Agents Phase 4
43 Antiemetics Phase 4
44 Contraceptives, Postcoital Phase 4
45 Contraceptives, Oral Phase 4
46 Contraceptive Agents Phase 4
47 Quetiapine Fumarate Phase 4 111974-72-2
48 Atomoxetine Hydrochloride Phase 4
49 Antibiotics, Antitubercular Phase 4
50 Antitubercular Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1641)
# Name Status NCT ID Phase Drugs
1 A Prospective Double Blind Randomized Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder Unknown status NCT00134446 Phase 4
2 A Double-Blind, Placebo-Controlled, Flexible-Dose Pilot Clinical Trial of Once-Daily Extended-Release Tramadol for the Treatment of PTSD Unknown status NCT01517711 Phase 4 Tramadol;Placebo
3 The Effect of 21-Days Intranasal Oxytocin on Clinical Symptoms and Social Function in Patients With Post Traumatic Stress Disorder (PTSD), a Randomized Controled Trail Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO
4 Early Pharmacological Intervention With Diazepam in the Emergency Room Setting to Prevent Posttraumatic Stress Disorder (PTSD). Unknown status NCT01221883 Phase 4 Diazepam
5 Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure Unknown status NCT00633685 Phase 4 Fluoxetine;Placebo
6 Double Blind, Placebo-Controlled Trial of THC as add-on Therapy for PTSD Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
7 A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder Unknown status NCT01535586 Phase 4
8 Propranolol Reactivation Mismatch (PRM) Treatment for PTSD: A Pilot Study Unknown status NCT03652922 Phase 4 Reactivation Mismatch
9 Suvorexant and Trauma Related Insomnia Unknown status NCT02704754 Phase 4 suvorexant
10 Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD) Completed NCT00203463 Phase 4 topiramate
11 Evaluation of the Efficacy of Vortioxetine for Posttraumatic Stress Disorder Completed NCT02637895 Phase 4 Placebo;Vortioxetine
12 Treatment for Psychogenic Nonepileptic Seizures: A Pilot, 12 Week, Prospective, Randomized, Placebo-controlled, Double-blind, Clinical Trial of Sertraline in the Treatment of Comorbid Psychiatric Disorders in NES Completed NCT00159965 Phase 4 sertraline;placebo
13 A Study of Sertraline to Prevent PTSD Completed NCT00182078 Phase 4 Placebo;Sertraline
14 A Placebo-controlled, Randomized, Double-blind Comparison of Placebo vs Short Course Low Dose Corticosteroids on Posttraumatic Stress Disorder (PTSD) Completed NCT00204737 Phase 4 prednisone;placebo
15 Combined Treatment With a Benzodiazepine (Clonazepam) and a Selective Serotonin Reuptake Inhibitor (Paroxetine) for Rapid Treatment of Posttraumatic Stress Disorder (PTSD) Completed NCT00025740 Phase 4 clonazepam and paroxetine
16 Combined Mirtazapine and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment of Post-traumatic Stress Disorder (PTSD) Completed NCT01178671 Phase 4 Mirtazapine;Sertraline
17 Randomized Trial of Sertraline, Prolonged Exposure, and Their Combination for Post-traumatic Stress Disorder (PTSD) in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF). Completed NCT01524133 Phase 4 Sertraline
18 Prophylaxis of Posttraumatic Stress Disorder With Post-Trauma Propranolol Completed NCT00158262 Phase 4 Propranolol;Placebo
19 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians Completed NCT00208130 Phase 4 Topiramate
20 Pilot Feasibility Study of Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder Completed NCT04188392 Phase 4 Pimavanserin
21 Risperidone Monotherapy in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma: a Double-Blind, Placebo Controlled, Randomized Clinical Trial Completed NCT00208182 Phase 4 Risperidone
22 Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study Completed NCT02287038 Phase 4 Atomoxetine 80 MG
23 Developing Memory Reconsolidation Blockers as Novel PTSD Treatments Completed NCT01490697 Phase 4 Mifepristone;d-Cycloserine;Placebo-matching Mifepristone;Placebo-matching d-Cycloserine (DCS)
24 The Effect of Intranasal Oxytocin on Emphatic Abilities in Patients With PTSD Completed NCT01325168 Phase 4 syntocinon nasal spray;placebo nasal spray
25 Neurofunctional Markers of SSRI Treatment Response in PTSD Completed NCT00700999 Phase 4 Paroxetine
26 Reducing Suicidal Ideation Through Treatment of Nightmares-PTSD Completed NCT02199652 Phase 4 Prazosin;Placebo
27 An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder Completed NCT02258828 Phase 4 Memantine;Placebo
28 Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy Completed NCT01087736 Phase 4 Topiramate
29 Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder Among Veterans of Operation Enduring Freedom and Iraqi Freedom (OEF/OIF) Completed NCT01271244 Phase 4 Escitalopram
30 Cognitive Behavioral Therapy vs. Sertraline in the Treatment of Post Traumatic Stress Disorder Completed NCT00391430 Phase 4 Sertraline
31 Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes Completed NCT00347269 Phase 4 Psychotropic medication optimization
32 Treatment of Sleep Disturbances in Trauma-affected Refugees: A Randomised Controlled Trial Completed NCT02761161 Phase 4 Mianserin
33 The Outcome of Treatment of Traumatised Refugees With Trauma-Focused Cognitive Behavioural Therapy and / or Antidepressants - a Randomised Controlled Trial Completed NCT00917397 Phase 4 Sertraline
34 The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy - a Randomised Clinical Study Completed NCT01569685 Phase 4 Venlafaxine;Sertraline
35 Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder Completed NCT00120250 Phase 4 Eszopiclone
36 Naltrexone and Cognitive-Behavioral Therapy for Patients With Alcoholism and Post-Traumatic Stress Disorder Completed NCT00006489 Phase 4 Naltrexone;Placebo
37 Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD) Completed NCT00560612 Phase 4 Paroxetine;Placebo
38 A Double-blind, Placebo-controlled Randomized Trial of Vilazodone in the Treatment of Posttraumatic Stress Disorder Completed NCT01715519 Phase 4 Treatment (Viibryd)
39 Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans Completed NCT03340350 Phase 4 Minocycline
40 Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder Completed NCT01681849 Phase 4 Placebo;Paroxetine
41 An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder Completed NCT01587118 Phase 4 Adjunctive asenapine
42 Effects of Paxil CR on Neural Circuits in PTSD Completed NCT00672776 Phase 4 paroxetine;placebo
43 Telemedicine Outreach for Post Traumatic Stress in CBOCs Completed NCT00821678 Phase 4
44 Eszopiclone for the Treatment of PTSD Completed NCT01605253 Phase 4 Eszopiclone;Placebo
45 Effects of THC on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study Completed NCT03008005 Phase 4 Placebo Oral Capsule;Dronabinol Cap 5 milligrams (MG);Dronabinol Cap 10 milligrams (MG)
46 Combination Treatment for PTSD After the WTC Attack Completed NCT01130103 Phase 4 Paroxetine
47 Geodon (Ziprasidone) for Posttraumatic Stress Disorder Completed NCT00208208 Phase 4 Ziprasidone
48 Effects of Hydrocortisone and D-Cycloserine on Fear Extinction in Veterans With Posttraumatic Stress Disorder Completed NCT00674570 Phase 4 Hydrocortisone;D-Cycloserine;Placebo
49 Randomized Clinical Trial to Study the Topiramate Efficacy for Posttraumatic Disorder Treatment Completed NCT00725920 Phase 4 Topiramate;placebo control group
50 A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol Completed NCT00709735 Phase 4 Propranolol;Placebo

Search NIH Clinical Center for Post-Traumatic Stress Disorder

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Lithium Aspartate
Lithium Carbonate
lithium citrate
Paroxetine Hydrochloride
Sertraline Hydrochloride
Tranylcypromine sulfate

Cochrane evidence based reviews: stress disorders, post-traumatic

Genetic Tests for Post-Traumatic Stress Disorder

Genetic tests related to Post-Traumatic Stress Disorder:

# Genetic test Affiliating Genes
1 Post-Traumatic Stress Disorder 29

Anatomical Context for Post-Traumatic Stress Disorder

MalaCards organs/tissues related to Post-Traumatic Stress Disorder:

Brain, Amygdala, Eye, Cortex, Heart, Prefrontal Cortex, Pituitary

Publications for Post-Traumatic Stress Disorder

Articles related to Post-Traumatic Stress Disorder:

(show top 50) (show all 30159)
# Title Authors PMID Year
Effects of mind-body exercise on PTSD symptoms, depression and anxiety in PTSD patients: A protocol of systematic review and meta-analysis. 61 42
33530251 2021
The Effect of Physiotherapy Group Intervention in Reducing Pain Disorders and Mental Health Symptoms among Syrian Refugees: A Randomized Controlled Trial. 42
33348794 2020
Five-year post-disaster mental changes: Mothers and children living in low-dose contaminated Fukushima regions. 42
33378404 2020
Association study of trauma load and SLC6A4 promoter polymorphism in posttraumatic stress disorder: evidence from survivors of the Rwandan genocide. 54 61
20441718 2010
A prospective study of serotonin transporter gene promoter (5-HTT gene linked polymorphic region) and intron 2 (variable number of tandem repeats) polymorphisms as predictors of trauma response to mild physical injury. 54 61
19895335 2010
The D2 dopamine receptor gene variant C957T affects human fear conditioning and aversive priming. 61 54
19900188 2010
Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. 61 54
19576571 2009
Candidate-gene approach in fibromyalgia syndrome: association analysis of the genes encoding substance P receptor, dopamine transporter and alpha1-antitrypsin. 61 54
20074437 2009
Serotonin transporter gene (SLC6A4) promoter polymorphisms and the susceptibility to posttraumatic stress disorder in the general population. 54 61
19487392 2009
Modification of the association between serotonin transporter genotype and risk of posttraumatic stress disorder in adults by county-level social environment. 54 61
19228812 2009
Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. 61 54
19897083 2009
Adrenocortical responsiveness to infusions of physiological doses of ACTH is not altered in posttraumatic stress disorder. 54 61
19893760 2009
The DRD2 gene 957C>T polymorphism is associated with posttraumatic stress disorder in war veterans. 61 54
18833581 2009
Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder. 54 61
18213623 2008
Blunted ACTH response to dexamethasone suppression-CRH stimulation in posttraumatic stress disorder. 61 54
18342888 2008
Effects of trauma-related audiovisual stimulation on cerebrospinal fluid norepinephrine and corticotropin-releasing hormone concentrations in post-traumatic stress disorder. 54 61
18295412 2008
Elevated plasma corticotrophin-releasing hormone levels in veterans with posttraumatic stress disorder. 54 61
18037027 2008
Mice that under- or overexpress glucocorticoid receptors as models for depression or posttraumatic stress disorder. 54 61
18037007 2008
Monoamine oxidase (MAO) intron 13 polymorphism and platelet MAO-B activity in combat-related posttraumatic stress disorder. 61 54
17289152 2007
The serotonin transporter genotype and social support and moderation of posttraumatic stress disorder and depression in hurricane-exposed adults. 61 54
17974934 2007
Glucocorticoid receptor activation is involved in producing abnormal phenotypes of single-prolonged stress rats: a putative post-traumatic stress disorder model. 61 54
17644267 2007
Mineralocorticoid receptor function in posttraumatic stress disorder after pretreatment with metyrapone. 54 61
16566900 2006
No association between the Clara cell secretory protein (CC16) gene polymorphism and personality traits. 61 54
16764982 2006
The D2 dopamine receptor (DRD2) gene is associated with co-morbid depression, anxiety and social dysfunction in untreated veterans with post-traumatic stress disorder. 61 54
16632165 2006
Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. 61 54
16325152 2006
Expression of c-fos and BDNF mRNA in subregions of the prefrontal cortex of male and female rats after acute uncontrollable stress. 61 54
15993862 2005
Glucocorticoid receptor polymorphisms and post-traumatic stress disorder. 54 61
15511603 2005
Neurobiological characteristics of rhesus macaque abusive mothers and their relation to social and maternal behavior. 61 54
15652254 2005
No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder. 61 54
15677606 2005
Increased adrenocorticotropin suppression after dexamethasone administration in sexually abused adolescents with posttraumatic stress disorder. 54 61
15677426 2004
Increased adrenocorticotropin suppression following dexamethasone administration in sexually abused adolescents with posttraumatic stress disorder. 54 61
15288707 2004
An increased capacity for adrenal DHEA release is associated with decreased avoidance and negative mood symptoms in women with PTSD. 61 54
15199367 2004
The ACTH response to dexamethasone in PTSD. 61 54
15285965 2004
Pituitary volumes in pediatric maltreatment-related posttraumatic stress disorder. 54 61
15039005 2004
Effect of topiramate on glucocorticoid receptor mediated action. 61 54
14666121 2004
Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. 61 54
14675802 2003
D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder. 54 61
12957328 2003
The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. 61 54
12606697 2003
Cerebrospinal fluid corticotropin-releasing factor (CRF) and vasopressin concentrations predict pituitary response in the CRF stimulation test: a multiple regression analysis. 61 54
12629539 2003
Flow cytometric determination of glucocorticoid receptor (GCR) expression in lymphocyte subpopulations: lower quantity of GCR in patients with post-traumatic stress disorder (PTSD). 61 54
12562397 2003
Endocrine and cardiovascular responses to corticotropin-releasing hormone in patients with posttraumatic stress disorder: a role for atrial natriuretic peptide? 54 61
12707494 2003
Mineralocorticoid receptor function in patients with posttraumatic stress disorder. 54 61
12411234 2002
The cortisol and glucocorticoid receptor response to low dose dexamethasone administration in aging combat veterans and holocaust survivors with and without posttraumatic stress disorder. 54 61
12242055 2002
Harmful drinking in military veterans with post-traumatic stress disorder: association with the D2 dopamine receptor A1 allele. 61 54
12217937 2002
Increased pituitary and adrenal reactivity in premenopausal women with posttraumatic stress disorder. 61 54
11750893 2001
Corticotropin-releasing hormone in depression and post-traumatic stress disorder. 54 61
11337099 2001
Predictors of treatment response in patients with posttraumatic stress disorder. 54 61
11294480 2001
Biology of posttraumatic stress disorder. 54 61
11495096 2001
The DRD2 gene in psychiatric and neurological disorders and its phenotypes. 54 61
11256581 2000
Platelet monoamine oxidase activity, ego strength, and neuroticism in soldiers with combat-related current posttraumatic stress disorder. 54 61
10810173 2000

Variations for Post-Traumatic Stress Disorder

Expression for Post-Traumatic Stress Disorder

Search GEO for disease gene expression data for Post-Traumatic Stress Disorder.

Pathways for Post-Traumatic Stress Disorder

Pathways related to Post-Traumatic Stress Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
8 11.12 SLC6A4 MAOA HTR2A
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways

GO Terms for Post-Traumatic Stress Disorder

Cellular components related to Post-Traumatic Stress Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.73 SLC6A4 HTR2A DRD2 DBH CRH CNR1
2 axon GO:0030424 9.55 HTR2A DRD2 COMT CNR1 BDNF
3 integral component of postsynaptic membrane GO:0099055 9.13 SLC6A4 HTR2A DRD2
4 integral component of presynaptic membrane GO:0099056 8.92 SLC6A4 HTR2A DRD2 CNR1

Biological processes related to Post-Traumatic Stress Disorder according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 OXTR NR3C1 IL1B HTR2A DRD2 CRH
2 G protein-coupled receptor signaling pathway GO:0007186 10.16 OXTR HTR2A DRD2 CRH CNR1 ADCYAP1R1
3 response to lipopolysaccharide GO:0032496 9.88 MAOB IL1B COMT CNR1
4 positive regulation of cold-induced thermogenesis GO:0120162 9.85 OXTR DBH ADCYAP1
5 response to toxic substance GO:0009636 9.83 SLC6A4 MAOB DRD2
6 negative regulation of cell death GO:0060548 9.8 DRD2 CRH ADCYAP1R1
7 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.77 DRD2 CNR1 ADCYAP1R1
8 sensory perception of pain GO:0019233 9.77 HTR2A CNR1 ADCYAP1
9 female pregnancy GO:0007565 9.76 OXTR CRH COMT ADCYAP1
10 response to ethanol GO:0045471 9.73 MAOB DRD2 CRH CNR1 ADCYAP1R1 ADCYAP1
11 positive regulation of vasoconstriction GO:0045907 9.7 OXTR HTR2A DBH
12 activation of phospholipase C activity GO:0007202 9.69 HTR2A BDNF ADCYAP1R1
13 behavioral response to cocaine GO:0048148 9.67 HTR2A DRD2
14 response to amphetamine GO:0001975 9.67 OXTR DRD2 DBH
15 regulation of synaptic transmission, GABAergic GO:0032228 9.66 DRD2 CNR1
16 catecholamine metabolic process GO:0006584 9.66 MAOA COMT
17 synaptic transmission, dopaminergic GO:0001963 9.65 DRD2 CRH
18 maternal behavior GO:0042711 9.65 OXTR DBH
19 associative learning GO:0008306 9.65 DRD2 DBH CRH
20 sleep GO:0030431 9.64 OXTR HTR2A
21 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.64 HTR2A DRD2
22 negative regulation of synaptic transmission GO:0050805 9.63 IL1B DRD2
23 positive regulation of growth hormone secretion GO:0060124 9.62 DRD2 ADCYAP1
24 negative regulation of potassium ion transport GO:0043267 9.62 HTR2A ADCYAP1
25 response to cocaine GO:0042220 9.62 OXTR DRD2 CRH CNR1
26 behavioral response to ethanol GO:0048149 9.61 DRD2 DBH
27 response to pain GO:0048265 9.61 DBH CRH COMT
28 positive regulation of cAMP-mediated signaling GO:0043950 9.58 CRH ADCYAP1R1 ADCYAP1
29 sperm ejaculation GO:0042713 9.57 SLC6A4 OXTR
30 positive regulation of fever generation GO:0031622 9.56 IL1B CNR1
31 response to drug GO:0042493 9.56 SLC6A4 OXTR MAOB HTR2A DRD2 CRH
32 negative regulation of serotonin secretion GO:0014063 9.55 MAOB CNR1
33 negative regulation of dopamine secretion GO:0033602 9.54 DRD2 CNR1
34 neurotransmitter catabolic process GO:0042135 9.54 MAOB MAOA COMT
35 dopamine catabolic process GO:0042420 9.46 MAOB MAOA DBH COMT
36 memory GO:0007613 9.1 SLC6A4 OXTR HTR2A DBH CNR1 BDNF

Molecular functions related to Post-Traumatic Stress Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 8.96 SLC6A4 HTR2A
2 primary amine oxidase activity GO:0008131 8.62 MAOB MAOA

Sources for Post-Traumatic Stress Disorder

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....